TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
LOS ANGELES, April 20, 2017 -- Lundin Law PC , a shareholder rights firm, announces the filing of a class action lawsuit against Lion Biotechnologies, Inc. (“Lion” or the “Company”) (Nasdaq:LBIO) concerning possible violations of federal securities laws between November 14, 2013 and April 10, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired the Company’s shares during the Class Period should contact the firm prior to the June 13, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, during the Class Period, Lion made false and/or misleading statements and/or failed to disclose: that the Company, through its former Chief Executive Officer (“CEO”) Manish Singh, engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion to potential investors that purported to be independent from the company when, in fact, they were paid promotions; that former CEO Singh engaged a notorious stock promotion firm to pay writers to publish articles about the Company on investment websites and to coordinate the distribution of articles to thousands of electronic mailboxes; that former CEO Singh actively participated in the promotional work for Lion Biotechnologies and understood that the promotion firm was using writers who would not disclose that Lion was indirectly compensating them for their publications; and that as a result of the above, Lion’s public statements were materially false and misleading at all relevant times.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
